Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. INO
stocks logo

INO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.366
-39%
--
--
-0.370
-27.45%
--
--
-0.277
-54.64%
Estimates Revision
The market is revising Downward the revenue expectations for Inovio Pharmaceuticals, Inc. (INO) for FY2025, with the revenue forecasts being adjusted by -13.2% over the past three months. During the same period, the stock price has changed by -27.60%.
Revenue Estimates for FY2025
Revise Downward
down Image
-13.2%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+18.48%
In Past 3 Month
Stock Price
Go Down
down Image
-27.60%
In Past 3 Month
Wall Street analysts forecast INO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INO is 7.33 USD with a low forecast of 3.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast INO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INO is 7.33 USD with a low forecast of 3.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 2.020
sliders
Low
3.00
Averages
7.33
High
13.00
Current: 2.020
sliders
Low
3.00
Averages
7.33
High
13.00
Piper Sandler
Edward Tenthoff
Overweight
maintain
$5 -> $6
2025-11-14
Reason
Piper Sandler
Edward Tenthoff
Price Target
$5 -> $6
2025-11-14
maintain
Overweight
Reason
Piper Sandler analyst Edward Tenthoff raised the firm's price target on Inovio to $6 from $5 and keeps an Overweight rating on the shares. The firm notes the company ended Q3 with cash of $50.8M and subsequently raised gross proceeds of $28.75M bringing pro forma cash to $77.3M, expected to fund operations into Q3 2026 through INO-3107 approval.
Piper Sandler
Edward Tenthoff
initiated
$5
2025-07-09
Reason
Piper Sandler
Edward Tenthoff
Price Target
$5
2025-07-09
initiated
Reason
Piper Sandler analyst Edward Tenthoff initiated coverage of Inovio with an Overweight rating and $5 price target. The company is is developing DNA-encoded medicines to treat cancer, infectious and rare diseases, the analyst tells investors in a research note. The firm says INO-3107, being developed to treat recurrent respiratory papillomatosis caused by human papillomavirus, was well tolerated and achieved robust clinical efficacy in a Phase I/II study.
Oppenheimer
Oppenheimer
Outperform
downgrade
$15 -> $13
2025-05-14
Reason
Oppenheimer
Oppenheimer
Price Target
$15 -> $13
2025-05-14
downgrade
Outperform
Reason
Oppenheimer lowered the firm's price target on Inovio to $13 from $15 and keeps an Outperform rating on the shares. The firm notes the company reported Q1 2025 results with $25.1M OpEx and cash balance of $68.4M, which is expected to provide runway into Q1 2026. Encouragingly, Inovio remains on track to initiate rolling BLA submission for INO-3107 in mid-2025, and subsequent filing completion in the second half of 2025 could support potential approval as early as mid-2026 if granted priority review, Oppenheimer adds.
HC Wainwright & Co.
Raghuram Selvaraju
Hold
Reiterates
$3
2025-03-19
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$3
2025-03-19
Reiterates
Hold
Reason
RBC Capital
Gregory Renza
Hold
Maintains
$6 → $5
2025-03-19
Reason
RBC Capital
Gregory Renza
Price Target
$6 → $5
2025-03-19
Maintains
Hold
Reason
RBC Capital lowered the firm's price target on Inovio to $5 from $6 and keeps a Sector Perform rating on the shares. The company continues to drive steady advancement of its diverse pipeline in the background, but attention remains squarely on the RRP opportunity, commercial setup, and Inovio's ability to execute, the analyst tells investors in a research note. RBC adds however that its reduced price target reflects the one-year cash runway for 3107's critical though risky path.
Citizens Capital Markets
Roy Buchanan
Buy
Reiterates
$18
2025-03-14
Reason
Citizens Capital Markets
Roy Buchanan
Price Target
$18
2025-03-14
Reiterates
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Inovio Pharmaceuticals Inc (INO.O) is -1.59, compared to its 5-year average forward P/E of -3.16. For a more detailed relative valuation and DCF analysis to assess Inovio Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.16
Current PE
-1.59
Overvalued PE
-0.26
Undervalued PE
-6.06

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.73
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.16
Undervalued EV/EBITDA
-4.62

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
404.67
Current PS
0.00
Overvalued PS
869.96
Undervalued PS
-60.62
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

INO News & Events

Events Timeline

(ET)
2025-11-11
08:44:30
Inovio Prices 13.16M Share Spot Secondary Offering at $1.90
select
2025-11-10 (ET)
2025-11-10
18:18:44
Inovio Reveals Common Stock Offering, Amount Not Disclosed
select
2025-11-10
16:14:01
Inovio Announces Q3 Earnings Per Share of 87 Cents, Exceeding Consensus Estimate of 48 Cents
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
11-18PRnewswire
INOVIO to Participate in December Investor Conferences

  • Investor Conferences Participation: INOVIO will participate in the Piper Sandler 37th Annual Healthcare Conference on December 2 and the Oppenheimer Movers in Rare Disease Summit on December 11, where they will engage in a fireside chat and a panel discussion, respectively.

  • Management Meetings: INOVIO's management team will conduct one-on-one meetings with investors during these conferences to discuss potential stock-moving catalysts related to their developments in DNA medicines.

  • Company Focus: INOVIO is dedicated to developing and commercializing DNA medicines aimed at treating and protecting against HPV-related diseases, cancer, and infectious diseases.

  • Technology Overview: The company utilizes innovative technology to optimize the design and delivery of DNA medicines, enabling the body to produce its own disease-fighting tools.

[object Object]
Preview
4.0
11-15NASDAQ.COM
Inovio (INO) Receives Upgrade to Buy: Reasons Behind the Decision

  • Inovio Pharmaceuticals Upgrade: Inovio Pharmaceuticals has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates, indicating a positive outlook for the company's stock price.

  • Zacks Rating System: The Zacks rating system, which evaluates stocks based on earnings estimate revisions, has a strong track record, with Zacks Rank #1 stocks averaging a +25% annual return since 1988.

  • Earnings Estimates: Analysts have raised their earnings estimates for Inovio, with a 5% increase in the Zacks Consensus Estimate over the past three months, reflecting an improvement in the company's underlying business.

  • Market Positioning: The upgrade places Inovio in the top 20% of Zacks-covered stocks, suggesting potential for near-term stock price increases driven by positive earnings revisions.

[object Object]
Preview
8.5
11-11SeekingAlpha
INOVIO reveals pricing details for $25 million public offering

  • Public Offering Announcement: INOVIO Pharmaceuticals has priced an underwritten public offering of 13.15 million shares at $1.90 per share, with all shares being sold by the company.

  • Closing Date and Additional Options: The offering is expected to close around November 12, and underwriters have a 30-day option to purchase an additional 1,973,700 shares at the same price.

  • Expected Proceeds: The gross proceeds from the offering are anticipated to be approximately $25 million.

  • Market Reaction: Following the announcement, INO's stock dropped 6% in premarket trading, with shares priced at $2.005.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Inovio Pharmaceuticals Inc (INO) stock price today?

The current price of INO is 2.02 USD — it has increased 0 % in the last trading day.

arrow icon

What is Inovio Pharmaceuticals Inc (INO)'s business?

Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.

arrow icon

What is the price predicton of INO Stock?

Wall Street analysts forecast INO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INO is 7.33 USD with a low forecast of 3.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Inovio Pharmaceuticals Inc (INO)'s revenue for the last quarter?

Inovio Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Inovio Pharmaceuticals Inc (INO)'s earnings per share (EPS) for the last quarter?

Inovio Pharmaceuticals Inc. EPS for the last quarter amounts to -0.87 USD, decreased -2.25 % YoY.

arrow icon

What changes have occurred in the market's expectations for Inovio Pharmaceuticals Inc (INO)'s fundamentals?

The market is revising Downward the revenue expectations for Inovio Pharmaceuticals, Inc. (INO) for FY2025, with the revenue forecasts being adjusted by -13.2% over the past three months. During the same period, the stock price has changed by -27.60%.
arrow icon

How many employees does Inovio Pharmaceuticals Inc (INO). have?

Inovio Pharmaceuticals Inc (INO) has 134 emplpoyees as of December 05 2025.

arrow icon

What is Inovio Pharmaceuticals Inc (INO) market cap?

Today INO has the market capitalization of 138.78M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free